Drugs / BZ371A
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05332340 | Nov 2022 | erectile dysfunction, prostate cancer | Biozeus Biopharmaceutical S.A. | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06651541 | Jul 2026 → Jun 2027 expected | physiological sexual disorder, sexual disorder | Biozeus Biopharmaceutical S.A. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06116045 | Oct 2024 → Feb 2025 overdue | sexual disorder | Biozeus Biopharmaceutical S.A. | Recruiting | No outcome recorded |
| Phase 2 | NCT05558007 | Nov 2023 → Dec 2024 overdue | erectile dysfunction, prostate cancer | Biozeus Biopharmaceutical S.A. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2025-10-07 | Biozeus Biopharmaceutical S.A. | Results Biozeus Completes Positive Phase II Trial in Women With FSIAD biozeus.com.br ↗
Rio de Janeiro & London – October 2025 – Biozeus Biopharmaceuticals S.A. today announced positive topline results from its Phase II clinical trial evaluating BZ371A, a first-in-class therapeutic peptide for the treatment of Female Sexual Interest/Arousal Disorder (FSIAD). |
| 2025-05-22 | Biozeus Biopharmaceutical S.A. | Results PHASE II CLINICAL TRIAL IN MEN WITH ERECTILE DYSFUNCTION biozeus.com.br ↗
THE STUDY MET ITS PRIMARY ENDPOINTS AND ACHIEVED ALL PRE-DEFINED DEVELOPMENT MILESTONES, CONFIRMING BOTH THE SAFETY AND EFFICACY OF BZ371A IN THIS HIGH-NEED POPULATION. |
| 2023-03-07 | Biozeus Biopharmaceutical S.A. | Results Phase I Trials for BZ371A to Erectile Dysfunction biozeus.com.br ↗
BZ371A IS BEING DEVELOPED FOR THE TREATMENT OF ERECTILE DYSFUNCTIONS AND WAS APPLIED TOPICALLY IN THE GENITAL AREA OF MEN AND WOMEN CONFIRMING LOCAL SAFETY, TOLERABILITY AND LACK OF SYSTEMIC EXPOSURE. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-10-07 | Biozeus Biopharmaceutical S.A. | Biozeus Completes Positive Phase II Trial in Women With FSIAD biozeus.com.br ↗ |
| 2025-05-22 | Biozeus Biopharmaceutical S.A. | PHASE II CLINICAL TRIAL IN MEN WITH ERECTILE DYSFUNCTION biozeus.com.br ↗ |
| 2023-03-07 | Biozeus Biopharmaceutical S.A. | Phase I Trials for BZ371A to Erectile Dysfunction biozeus.com.br ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BZ371A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06116045 ↗ |
| Route | Topical | “topically administered” NCT05332340 ↗ |